New Zealand markets closed

Palisade Bio, Inc. (PALI)

NasdaqCM - NasdaqCM Real-time price. Currency in USD
Add to watchlist
4.7100-0.3600 (-7.10%)
At close: 04:00PM EDT
4.6700 -0.04 (-0.85%)
After hours: 07:21PM EDT
Full screen
Trade prices are not sourced from all markets
Previous close5.0700
Open4.6800
Bid3.6200 x 200
Ask5.9200 x 200
Day's range4.5020 - 5.0400
52-week range3.8200 - 36.6000
Volume145,573
Avg. volume697,085
Market cap4.01M
Beta (5Y monthly)1.46
PE ratio (TTM)N/A
EPS (TTM)-27.0000
Earnings date10 May 2024 - 14 May 2024
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est33.75
  • GlobeNewswire

    Palisade Bio Successfully Demonstrates Bioactivation of PALI-2108 In Ex-Vivo Study of Normal Healthy and Ulcerative Colitis Patients’ Stool

    Company continues advancing ongoing development of targeted therapies for ulcerative colitis (UC) Carlsbad, CA, April 16, 2024 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade”, “Palisade Bio” or the “Company”), a biopharmaceutical company focused on developing and advancing novel therapeutics for patients living with autoimmune, inflammatory, and fibrotic diseases, announced today the successful completion of its analysis evaluating ex-vivo bioactivation of PALI-2108, an orally

  • GlobeNewswire

    Palisade Bio to Participate in the Virtual Investor Lunch Break Event

    – Live webcast with members of Palisade Bio management on Tuesday, April 16th at 12:00 PM ET Carlsbad, CA, April 11, 2024 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade”, “Palisade Bio” or the “Company”), a biopharmaceutical company focused on developing and advancing novel therapeutics for patients living with autoimmune, inflammatory, and fibrotic diseases, today announced that it will present at the Virtual Investor Lunch Break Featuring Palisade Bio event on Tuesday, April

  • GlobeNewswire

    Palisade Bio Presents Development Overview of PALI-2108 at the IBD Innovate: Product Development for Crohn’s & Colitis™

    – PALI-2108 in development for the treatment of moderate-to-severe ulcerative colitis (UC) advancing towards Phase 1 clinical study before year end Carlsbad, CA, April 10, 2024 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade”, “Palisade Bio” or the “Company”), a biopharmaceutical company focused on developing and advancing novel therapeutics for patients living with autoimmune, inflammatory, and fibrotic diseases, today announced that it presented at IBD Innovate: Product Develo